The role of non-steroidal anti-inflammatory drugs in the chemoprevention of breast cancer

Pharmaceuticals

Volumn 3, Issue 5, 2010, Pages 1550-1560

  Horn, Sarah L ^a   Fentiman, Ian S ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Chemoprevention; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; AROMATASE INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2; ESTRADIOL; ESTROGEN RECEPTOR; HORMONE RECEPTOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR; ROFECOXIB; SULINDAC; TRASTUZUMAB;

AGE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER STAGING; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COHORT ANALYSIS; COLON POLYP; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; HUMAN; LUNG CANCER; MONOTHERAPY; NONHUMAN; OSTEOARTHRITIS; PEPTIC ULCER; POSTMENOPAUSE; PROSTAGLANDIN SYNTHESIS INHIBITION; PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; RISK REDUCTION; SIDE EFFECT;

EID: 77954939805     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3051550     Document Type: Article

References (52)

1. Cuzick, J.; Wang, D.Y., Bulbrook, R.D. The prevention of breast cancer. Lancet 1986, 327, 83-86.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Systemic treatment of early breast cancerby hormonal, cytotoxic, or immune therapy. Lancet 1992, 339, 71-85.
3. Fischer, B.; Constantino, J.B.; Wickherham, D.L.; Redmond, C.K.; Kavanah, M.; Cronin, W.M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel P-1 study. J. Natl. Cancer. Inst. 1998, 90, 1371-1388.
4. Cuzick, J.; Forbes, J.; Sestak, I.; Cawthorn, S.; Hamed, H.; Holli, K.; Howell, A. Long-term results of tamoxifen prophylaxis for breast cancer: 96 month follow-up of the randomised IBIS-1 trial. J. Natl. Cancer Inst. 2007, 99, 272-282.
5. Prichard, R.S.; Hill, A.D.; Dijkstra, B.; McDermott, E.W.; O'Higgins, N.J. The prevention of breast cancer. Br. J. Surg. 2003, 90(7), 772-783.
6. Cummings, S.R.; Eckert, S.; Krueger, K.A.; Grady, D.; Powles, T.J.; Cauley, J.A.; Norton, L.; Nickelsen, T.; Bjarnason, N.H.; Morrow, M.; Lippman, M.E.; Black, D.; Glusman, J.E.; Costa, A.; Jordan, V.C. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA 1999, 281, 2189-2197.
7. Bennett, A.; Berstock, D.A.; Carroll, M.A.; Stamford, I.F.; Wilson, A.J. Breast cancer, its recurrence and patient survival in relation to tumour prostaglandins. Adv. Prostaglandin Thromboxane Leukot Res. 1983, 12, 299-302.
8. Cuzick, J.; Otto, F.; Baron, J.A.; Burn, J.; Burn, J.; Greenwald, P.; Jankowski, J.; Vecchia, C.L.; Meyskens, F.; Senn, H.J.; Thun, M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol. 2009, 10, 501-507.
9. Pfizer Inc. 2004. Pfizer statement on new information regarding cardiovascular safety of celebrex. http://www.pfizer.com, accessed on 14 May 2010.
10. Arber, N.; Eagle, C.J.; Spicak, J.; Rácz, I.; Dite, P.; Hajer, J.; Zavoral, M.; Lechuga, M.J.; Gerletti, P.; Tang, J.; Rosenstein, R.B.; Macdonald, K.; Bhadra, P.; Fowler, R.; Wittes, J.; Zauber, A.G.; Solomon, S.D.; Levin, B. Celecoxib for the prevention of colorectal adenomatous polyps. New England J. Med. 2006, 355, 855-995.
11. Harris, R.E. COX-2 blockade in the chemoprevention of cancers of the colon, breast prostate and lung. Inflammopharmacology 2009, 17, 55-67.
12. Terry, M.B.; Gammon, M.D.; Zhang, F.F.; et al. Association of frequency and duration of aspirin use and hormone receptor stauts with breast cancer risk. JAMA 2004, 20, 2433-2440.
13. Davies, G.; Martin, L.A.; Sacks, N.; Dowsett, M. Cyclooxygenase(COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann. Oncol. 2002, 13, 669-678.
14. Harris, R.E.; Kasbari, S.; Farrar, W.B. Prospective study of non-steroidal anti-inflammatory drugs and breast cancer. Oncol. Rep. 1999, 6, 71-73.
15. Harris, R.E.; Chlebowski, R.T.; Jackson, R.D.; Frid, D.; Ascenseo, J.L.; Anderson, G.; Loar, A.; Rodabough, R.J.; White, E.; McTiernan, A. Breast cancer and non-steroidal anti-inflammatory drugs: prospective research from the women's health initiative. Cancer Res. 2003, 63, 6096-6101.
16. Marshall, S.F.; Bernstein, L.; Anton-Culver, H.; Deapon, D.; Horn-Ross, P.L.; Mohrenweiser, H.; Peel, D.; Pinder, R.; Purdie, D.M.; Reynolds, P.; Stram, D.; West, D.; Wright, W.E.; Ziogas, A.; Ross, R.K. Non-steroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J. Natl. Cancer Inst. 2005, 97, 805-812.
17. Harris, R.E.; Beebe-Donk, J.; Alshafie, G.A. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: A case control study. Int. J. Biol. Sci. 2007, 13, 328-334.
18. Chen, J.H.; Liu, T.Y.; Wu, C.W.; Chi, C.W. Non steroidal anti-inflammatory drugs for the treatment of advanced gastric cancer: Cyclo-oxgenase 2 is involved in hepatocyte growth factor mediated tumour development and progression. Med. Hypotheses 2001.57, 503-505.
19. Ristimäki, A.; Sivula, A.; Lundin, J.; Lundin, M.; Salminen, T.; Haglund, C.; Joensuu, H.; Isola, J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62, 632-635.
20. Subbaramaiah, K.; Norton, L.; Gerald, W.; Dannenberg, A.J. Cyclooxygenase is overexpressed in HER-2/neu-positive breast cancer: Evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 2002, 277, 18649-18657.
21. Witton, C.J.; Hawe, S.J.; Cooke, T.G.; Bartlett, J.M. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in estrogen receptor negative, but not estrogen receptor positive, breast cancer. Histopathology 2004, 45, 47-54.
22. Blair, C.K.; Sweeney, C.; Anderson, K.E.; Folsom, A.R. Nonsteroidal anti-inflammatory drug use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res. Treat. 2007, 101, 191-197.
23. Brodie, A.M.; Lu, Q.; Long, B.J.; Fulton, A.; Chen, T.; Macpherson, N.; DeJong, P.C.; Blankenstein, M.A.; Nortier, J.W.R.; Slee, P.H.T.J.; van de Ven, J.; van Gorp, J.M.H.H.; Elbers, J.R.J.; Schipper, M.E.I.; Blijham, G.H.; Thijssen, J.H. Aromatase and cyclooxygenase-2 expression in human breast cancers. J. Steroid Biochem. Mol. Biol. 2001, 79, 41-47.
24. Harris, R.E.; Alshafie, G.A.; Seibert, K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res. 2000, 60, 2101-2103.
25. Kubatka, P.; Ahlers, I.; Ahlersová, E.; Adámeková, E.; Luk, P.; Bojková, B.; Marková M. Chemopreventuon of mammary carcinogenesis in female rats by rofecoxib. Cancer Lett. 2003, 202, 131-136.
26. Mazhar, D.; Ang, R.; Waxman, J. COX inhibitors and breast cancer. Br. J. cancer 2006, 94, 346-350.
27. Zelnak. A.B.; O'Regan, R.M. Chemoprevention of breast cancer. Curr. Probl. Cancer 2004, 28, 201-217.
28. Singh-Ranger, G.; Mobkel, K. The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur. J. Surg. Oncol. 2002, 28, 729-737.
29. Muller-Decker, K.; Berger, I.; Ackermann, K.; Ehemann, V.; Zoubova, S.; Aulmann, S.; Pyerin, W.; Fürstenberger, G. Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. Am. J. Path. 2005, 166, 575-584.
30. Díaz-Cruz, E.S.; Brueggemeier, R.W. Interrealtionships between cyclooxygenases and aromatase: Unravelling the relevance of COX inhibitors in breast cancer. Anticancer Agents Med. Chem. 2006, 6, 221-232.
31. Zhao, Y.; Zhu, S.; Li, X.; Wang, F.; Hu, F.-L.; Li, D.-D.; Zhang, W.-C.; Li, X. Association between NSAID use and breast cancer risk: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2009, 117, 141-150.
32. Khuder, S.A.; Mutgi, A.B. Breast cancer and NSAID se a meta-analysis. Br. J. Cancer 2001, 85, 1188-1192.
33. Mangiapne, S.; Blettner, M.; Schlattmann, P. Aspirin use and breast cancer risk: A meta-analysis and meta-regression of observational studies from 2001-2005. Pharmcoepidemiol. Drug saf. 17, 115-124.
34. Friis, S.; Thomassen, L.; Sørensen, H.T.; Tjønneland, A.; Overvad, K.; Cronin-Fenton, D.P.; Vogel, U.; McLaughlin, J. K.; Blot, W.J.; Olsen, J.H. Non-steroidal anti-inflammatory drug use and breast cancer risk: A Danish Cohort study. Eur. J. Cancer Prev. 2008, 17, 88-96.
35. Khalkhali-Ellis, Z.; Hendrix, M.J. Nitric oxide regulation of maspin expression in normal mammary epithelial and breast cancer cells. Am. J. Pathol. 1994, 263, 526-529.
36. Girish, G.V.; Sinha, N.; Chakraborty, K.; Bhattacharya, G.; Kahn, N.N.; Sinha, A.K. Restoration of impaired plasma maspin level in human breast cancer. Acta Oncol. 2006, 45, 526-529.
37. Kashfi, K.; Rigas, B. Molecular targets of nitric-oxide- donating aspirin in cancer. Biochem. Soc. Trans. 2005. 33, 701-704.
38. Cavalieri, E.L.; Rogan, E.G. Depurinating estrogen-DNA adducts in the etiology and prevention of breast ad other cancers. Future oncol. 2010, 6, 75-91.
39. Boland, G.P.; Butt, I.S.; Prasad, R.; Knox, W.F.; Bundred, N.J. Cox-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br. J. Cancer 2004. 90, 423-429.
40. Tan, K.B.; Yong, W.P.; Putti, T.C. COX-2 expression: A potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 2004, 44, 24-28.
41. Zhang, Y.Q.; Coogan, P.F.; Palmer, J.R.; Strom, B.L.; Rosenberg, L. Use of non-steroidal antiinflammatory drugs and risk of breast cancer: The case control surveillance study revisited. Am. J. Epidemiol. 2005, 162,165-170.
42. Kirsch, V.A.; Kreiger, N.; Cotterchio, M.; Sloan, M.; Theis, B. Non-steroidal anti-inflammatory drugs use and breast cancer risk: Subgroup findings. Am. J. Epidemiol. 2007, 166, 709-716.
43. McCarthy, K.; Bustin, S.A.; Ogunkolade, B.; Khalaf, S.; Laban, C.A.; McVittie, C.J.; Carpenter, R.; Jenkins, P.J. Cyclooxygenase-2 mRNA expression and hormone receptor staus in breast cancer. Eur. J. Surg. Oncol. 2006, 32, 707-709.
44. Sharp, C.R.; Collet, J.P.; McNutt, M.; Belzile, E.; Boivin, J.-F.; Hanley, J.A. Nested case-control study of the effects of nonsteroidal anti-inflammatory drugs on breast cancer risk and stage. Br. J. Cancer 2000. 83, 112-120.
45. Falandary, C.; Canney, P.A.; Freyer, G.; Dirix, L.Y. Role of combination therapy with aromatase and cox-2 inhibitors in patients with metastatic breast cancer. Ann. Oncol. 2009, 20, 615-620.
46. Daidone, M.G.; Coradini, D.; Martelli, G.; Veneroni, S. Primary breast cancer in elderly women: Biological profile and relayion with clinical outcome. Crit. Rev. Oncol. Haematol. 2003, 45, 313-325.
47. Gennari, R.; Curgliano, G.; Rotmensz, N.; Robertson, C.; Colleoni, M.; Zurrida, S.; Nolè, F.; de Braud, F.; Orlando, L.; Leonardi, M.C.; Galimberti, V.; Intra, M.; Veronesi, P.; Renne, G.; Cinieri, S.; Audisio, R.A.; Luini, A.; Orecchia, R.; Viale, G.; Goldhirsch, A. Breast carcinoma in elderly women. Cancer 2004, 101, 1302-1310.
48. Fisher, C.J.; Egan, M.K.; Smith, P.; Wicks, K.; Millis, R.R.; Fentiman, I.S. Histopathology of breast cancer in elation to age. Br. J. Cancer 1997, 75, 593-596.
49. Pike, M.C.; Krailo, M.D.; Henderson, B.E.; Casagrande, J.T.; Hoel, D.G. Hormonal risk factors, breast tissue age and the age-incidence of breast cancer. Nature 1983, 303, 767-770.
50. Johnson, T.W.; Anderson, K.E.; Lazovich, D.; Folsom, A.R. Association of aspirin and nonsteroidal anti-inflammatory drugs use drug use with breast cancer. Cancer Epidemiol. Biomarkers Prev. 2002, 11, 1586-1591.
51. Sauter, E.W.; Qin, W.; Schlatter, L.; Hewitt, J.E.; Flynn, J.T. Celecoxib decreases prostaglandin E 2 concentrations in the nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. BMC Cancer 2006, 101, 191-197.
52. Agrawal, A.; Fentiman, I.S. NSAIDs and breast cancer: A possible prevention and treatment strategy. Int. J. Clin. Practice 2008, 62, 444-449